Jason J. Luke, Margaret K. Callahan, Michael A. Postow, Emanuela Romano, Nikhil Ramaiya, Mark Bluth, Anita Giobbie-Hurder, Donald P. Lawrence, Nageatte Ibrahim, Patrick A. Ott, Keith T. Flaherty, Ryan J. Sullivan, James J. Harding, Sandra D'Angelo, Mark Dickson, Gary K. Schwartz, Paul B. Chapman, Jedd D. Wolchok, F. Stephen Hodi and Richard D. Carvajal Clinical activity of ipilimumab for metastatic uveal melanoma Cancer 119
Article first published online: 2 AUG 2013 | DOI: 10.1002/cncr.28282
Ipilimumab can induce clinical responses and durable stable disease, with manageable toxicity, in metastatic uveal melanoma. Eastern Cooperative Oncology Group performance status and pretreatment low-density lipoprotein levels correlate with improved survival in multivariate analysis, and the week-7 absolute lymphocyte count may represent a biomarker of treatment efficacy.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field